Webcast Bridging the Gaps in Inflammatory bowel disease (IBD)

On November 16th 2021, this webcast was broadcast live. Did you miss the broadcast? Pre-register here and we will inform you when the webcast will be available on demand. 

What do we know about Inflammatory bowel disease (IBD)? What is the impact of the symptoms and what are the expectations of patients with IBD and their practitioners regarding remission, response, control and use of steroids?

In this webcast prominent speakers share their knowledge and experiences from daily practice and provide tools to build a bridge between patient and practitioner.

Experts

• prof. dr. David Rubin, gastro-enterologist, Uchicago Medicine, Chicago, USA
• prof. dr. Marieke Pierik, gastro-enterologist, Maastricht UMC, Maastricht
• dr. Marjolijn Duijvestein, gastro-enterologist, RadboudUMC, Nijmegen
• prof. dr. Geert D’Haens, gastro-enterologist, Amsterdam UMC, Amsterdam (moderator)

Date

This webcast will be broadcast on Tuesday 16th of November 2021 from 20.30 to 22.00 PM.

Audience

This webcast is primarily intended for gastro-enterologists and prescribing nurse specialists. Other interested healthcare professionals are welcome to join.

Accreditation

Accreditation has been requested from  NVMDL and VSR.

Easy registration

Create an account or log in with your existing account on mednet.nl to join the webcast.

Free webcast

Participation in this webcast is free of charge.

Questions?

If you have any questions, please send and email to nascholing@springer.com.

 

This webcast is sponsored by

IMM-NL-2100021

In the context of GDPR, Springer complies with the laws and regulations as laid down by this law. For this webcast it applies that it concerns a collaboration between Springer and Bristol Myers Squibb and that they each determine their own purpose and means in the processing of personal data. Springer and Bristol Myers Squibb are therefore separately responsible for processing. The privacy conditions that apply can be found here: Springer Healthcare & Bristol Myers Squibb.